why choose us

First received: October 13, 2023

Clinical Trial: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Head and Neck Cancer

Study Type: INTERVENTIONAL


Official Title: Administration of T Cells Expressing Chondroitin-Sulfate-Proteoglycan-4 Specific Chimeric Antigen Receptors (CAR) in Subjects With Head and Neck Squamous Cell Carcinoma (HNSCC)

Brief Summary: The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells) in patients with head and neck cancer that came back after receiving standard therapy for this cancer.The iC9.CAR-CSPG4 treatment is experimental and has not been approved by the Food and Drug Administration.How many (dose) of the iC9.CAR.CSPG4 T cells are safe to use in patients without causing too many side…

Read more